Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Friday, June 30, 2023 1 min read
Key Takeaway: AbbVie Inc. has updated its financial guidance for the quarter ended June 30, 2023, reflecting the impact of acquired IPR D and milestones expenses. The company's adjusted diluted EPS range for Q2 2023 is adjusted to between $2.75 and $2.85, factoring in an expense of $280 million. For the full year, the guidance for adjusted diluted EPS is revised to between $10.57 and $10.97. This updated guidance provides insight into AbbVie's financial management and planning amidst incurred expenses.
Market Sentiment Analysis
POSITIVE FACTORS
The adjusted diluted EPS guidance remains relatively stable.
AbbVie maintains transparency with its financial guidance.
The company shows proactive management of its expenses.
CONCERNS & RISKS
The acquired IPR D and milestones expense has a negative impact on FY 2023 EPS.
Q2 2023 expenses could influence profitability.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended June 30, 2023
Full-Year Ended December 31, 2023
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q2 2023 acquired IPR D and milestones expense
$
-
$
2.90
$
3.00
$
150
$
10.72
$
11.12
Q2 2023 acquired IPR D and milestones expense
280
(0.15)
(0.15)
280
(0.15)
(0.15)
Guidance including Q2 2023 acquired IPR D and milestones expense a
$
280
$
2.75
$
2.85
$
430
$
10.57
$
10.97
a The Company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the second quarter of 2023, as both cannot be reliably forecasted.
Frequently Asked Questions
What is the Q2 2023 acquired IPR D expense?
The acquired IPR D and milestones expense for Q2 2023 is $280 million.
How does Q2 2023 impact adjusted EPS?
Including Q2 2023 expenses, the adjusted diluted EPS range is $2.75 to $2.85.
What is the full-year EPS guidance?
The full-year adjusted diluted EPS is projected between $10.57 and $10.97.
What was the previous EPS guidance?
Previously, the adjusted diluted EPS guidance was between $2.90 and $3.00.
Is future IPR D expense predictable?
No, future acquired IPR D and milestones expenses are not reliably forecasted.